Literature DB >> 18286513

Delayed intervention of sporadic renal masses undergoing active surveillance.

Paul L Crispen1, Rosalia Viterbo, Eric B Fox, Richard E Greenberg, David Y T Chen, Robert G Uzzo.   

Abstract

BACKGROUND: Prompt surgical management remains the standard of care for renal cell carcinoma (RCC). Occasionally, it is necessary to postpone or delay surgical treatment. The authors of this report assessed whether delayed intervention following a period of active surveillance altered minimally invasive or nephron-sparing treatment plans, increased the risk of stage progression, and/or decreased recurrence-free survival rates.
METHODS: The authors searched their institutional kidney cancer database to identify small (< or =4 cm in greatest dimension on presentation), enhancing renal masses for which treatment initially was delayed or refused. Clinical, radiographic, and pathologic records were reviewed to determine linear tumor growth kinetics, alterations in treatment plan, stage migration, and cancer-specific outcomes related to delayed intervention.
RESULTS: Eighty-seven sporadic, localized, enhancing renal masses were identified in 82 patients who had management postponed for a median of 14 months (mean, 21 months; range, 6-97 months). Median tumor diameter was 2.0 cm on presentation. Treatment in 60 of 87 tumors (69%) was delayed for > or =12 months, and treatment was delayed for > or =24 months in 29 of 87 tumors (33%). Overall, 66 of 87 tumors (76%) underwent nephron-sparing approaches. In addition, 52 of 87 tumors (60%) were treated in a minimally invasive fashion. Pathology confirmed RCC in 73 of 87 treated tumors (84%). Fourteen of 54 tumors (26%) that were treated by surgical extirpation were high-risk tumors, and 3 of 54 tumors (6%) were upstaged on pathologic review.
CONCLUSIONS: The majority of small, sporadic, clinically localized renal tumors demonstrated slow interval growth. The management of these lesions may be delayed cautiously without limiting or complicating the available treatment options or incurring a high risk of disease progression.

Entities:  

Mesh:

Year:  2008        PMID: 18286513     DOI: 10.1002/cncr.23268

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  33 in total

1.  Active surveillance as the preferred management option for small renal masses.

Authors:  Ricardo A Rendon
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

2.  Renal masses--to treat or not to treat? If that is the question are contemporary biomarkers the answer?

Authors:  Robert G Uzzo
Journal:  J Urol       Date:  2008-06-11       Impact factor: 7.450

Review 3.  Imaging Protocols for Active Surveillance in Renal Cell Carcinoma.

Authors:  Christine W Liaw; Jared S Winoker; Reza Mehrazin
Journal:  Curr Urol Rep       Date:  2018-08-13       Impact factor: 3.092

4.  Small renal masses: the effect of illness uncertainty during active surveillance.

Authors:  Paul L Crispen
Journal:  Nat Rev Urol       Date:  2013-04-02       Impact factor: 14.432

Review 5.  The role of imaging in the active surveillance of small renal masses.

Authors:  P G K Wagstaff; P J Zondervan; J J M C H de la Rosette; M P Laguna
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

6.  Enhancing renal tumors in patients with prior normal abdominal imaging: further insight into the natural history of renal cell carcinoma.

Authors:  Paul L Crispen; Aldiana Soljic; Gregory Stewart; Alexander Kutikov; Daniel Davenport; Robert G Uzzo
Journal:  J Urol       Date:  2012-08-15       Impact factor: 7.450

Review 7.  Focal therapy for kidney cancer: a systematic review.

Authors:  Alexander Kutikov; David A Kunkle; Robert G Uzzo
Journal:  Curr Opin Urol       Date:  2009-03       Impact factor: 2.309

8.  Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.

Authors:  Alexander Kutikov; Brian L Egleston; Yu-Ning Wong; Robert G Uzzo
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

9.  Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance.

Authors:  Paul L Crispen; Rosalia Viterbo; Stephen A Boorjian; Richard E Greenberg; David Y T Chen; Robert G Uzzo
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

10.  Metastatic renal cell carcinoma risk according to tumor size.

Authors:  R Houston Thompson; Jennifer R Hill; Yuriy Babayev; Angel Cronin; Matt Kaag; Shilajit Kundu; Melanie Bernstein; Jonathan Coleman; Guido Dalbagni; Karim Touijer; Paul Russo
Journal:  J Urol       Date:  2009-05-17       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.